In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
A new genome-wide association study involving data from thousands of 23andMe customers implicated six loci in gestational duration or preterm birth risk.
The study details the validation of the mass spec-based preterm birth test, which the company launched nationwide last month through its agreement with LabCorp.
In PLOS this week: variants linked to risk of preterm birth, microbiome of New York's money, and more.
The agreement will allow Sera to leverage LabCorp's sales force and networks, but similar deals have failed to deliver for proteomics firms in the past.
Sera plans to make the test for preterm birth available nationwide this year with LabCorp as the exclusive US distributor.
A health-economic model of the company's preterm birth test found it could lower infant mortality by 23 percent and yield annual savings of around $500 million.
The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.
The study generated a number of three-protein panels that identified women at risk of giving birth preterm with sensitivity and specificity of above 80 percent.
According to one physician familiar with the test, it is a much needed diagnostic tool, but without insurance coverage it is too expensive for wide use.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.